Navigation Links
Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
Date:6/22/2012

PHILADELPHIA and REHOVOT, Israel, June 22, 2012 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic assays, today announced that the Company has entered into an agreement and release (the "Release Agreement") with the holders of the $1,750,000 senior secured debenture (the "Debenture") the Company sold and issued on January 27, 2012.

The Debenture had a maturity date of January 26, 2013 and accrued interest initially at a rate of 10% per annum, payable semi-annually. Beginning on March 15, 2012, an aggregate of $300,000 in principal amount of the Debenture became convertible, subject to certain limitations, into the Company's ordinary shares at a conversion price of $1.416 per share (after giving effect to the 1-for-15 reverse split of the Company's ordinary shares effected on May 14, 2012). The Debenture was secured by a security interest in all current and future assets of Rosetta and any current or future subsidiary, including Rosetta Genomics Inc.

Under the Release Agreement, Rosetta prepaid an aggregate of $1,450,000 in principal and $288,000 in interest and the Debenture holders agreed to convert the remaining $300,000 in principal into ordinary shares at the conversion price of $1.416 per share no later than July 31, 2012. 

Upon the prepayment of the $1,450,000 in principal and $288,000 in interest, all of the Company's obligations (other than the obligation to convert the remaining $300,000 in principal amount into ordinary shares) under the transaction agreements were satisfied or terminated and the security interest in all current and future assets of Rosetta and any current or future subsidiary terminated. 

"We are very pleased to pay off our secured loan as this Release Agreement not only retires our debt , it frees up our assets from the liens on them, all
'/>"/>

SOURCE Rosetta Genomics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
2. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
3. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
4. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
5. BioMed Realty, L.P. Prices $250 Million Offering Of 4.25% Senior Unsecured Notes Due 2022
6. BioMed Realty Trust Completes $400 Million Senior Unsecured Term Loan Financing
7. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
8. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
9. CannaBANK Acquires Rights to License PharmaSpheres Patented Growth System
10. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
11. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... that the 30-day review period following the filing ... ocular indications with the U.S. Food and Drug ... now active. Logo -  ...
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015  MicuRx ... antibiotics, today announced positive top-line results from the ... drug candidate MRX-I. MRX-I is an oral oxazolidinone ... MRSA and VRE, while offering physicians and patients ... currently available oxazolidinone agents. "These ...
(Date:8/31/2015)... LabStyle Innovations Corp. (OTCQB: DRIO), developer ... it recently closed a round of funding totaling ... support the global rollout and initial U.S. commercial ... management solution that includes novel software applications combined ... device, and for working capital purposes. The Dario ...
(Date:8/31/2015)... Grove, IL (PRWEB) , ... August 31, 2015 ... ... impurities (PGIs), as a high priority in the drug development approval process. Thus, ... , This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... Pearl Therapeutics announced,today that it has secured $8 ... Silicon Valley Bank, a member company of SVB Financial,Group ... will be drawn in two,tranches. , ... Oxford and SVB. They are,experienced and committed lenders ...
... 24 An investor group in Trinity,Biotech plc (Nasdaq: ... manufacturer of,diagnostic products, has petitioned the Office of the ... law provisions designed,to permit communication between shareholders and prospective ... filed asserts that Irish-based independent directors,Peter Coyne of Allied ...
... VITAS Innovative Hospice Care(R) announced,today that Christopher ... chief,information officer. In his new position, Rieder will ... to support the company,s,strategic direction. , ... of IT experience with global organizations,translating business objectives ...
Cached Biology Technology:Pearl Therapeutics Secures $8 Million in Debt Financing 2Pearl Therapeutics Secures $8 Million in Debt Financing 3VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer 2
(Date:8/5/2015)... Aug. 5, 2015 The biosensors market is ... applications, penetration into newer sectors, and development of devices ... biosensors space has seen the entry of multiple participants ... far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( http://www.frost.com/nee9 ...
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... air pollutant that harms humans and plants. Both climate and ... Researchers at the University of Gothenburg, Sweden, have now shown ... risk of ozone damage to plants in northern and central ... risk of ozone damage to vegetation is mainly due to ...
... German . When a cell divides, the ... to the daughter cells. Researchers at the Friedrich Miescher Laboratory ... a model organism. In cooperation with researchers at the University ... Aurora enzymes, which were already recognized as important cellular tools ...
... of engineers and scientists at the University of British Columbia ... eye for controlled and on-demand release of drugs to treat ... leading cause of vision loss among patients with diabetes. The ... in the retina, which in its advanced stages can result ...
Cached Biology News:Climate change increases the risk of ozone damage to plants 2New tasks attributed to Aurora proteins in cell division 2New tasks attributed to Aurora proteins in cell division 3UBC researchers invent new drug delivery device to treat diabetes-related vision loss 2
... SAPK/JNK (Thr183/Tyr185) Antibody Kit Kit ... Catalog #9251, 200 ul SAPK/JNK (56G8) ... SAPK/JNK Cell Extracts, Catalog #9253, (4 ... Catalog #7074, 100 ul Anti-biotin IgG, ...
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Biology Products: